Connely and colleagues have shown that crizotinib, a small-molecule inhibitor of c-Met, suppresses HGF/c-Met signaling and RhoA activation thereby preventing peritoneal dissemination in PDA [149]. The gene discussed is MET; the disease is Patent ductus arteriosus.